RET and non-small cell lung carcinoma: This approval was based on a single-arm phase I/II trial, LIBRETTO-001, which demonstrated overall tumor response rates of 85 and 64% for patients with RET-fusion positive NSCLC who were treatment naïve and previously treated, respectively [17, 18].